<code id='3DB526F2EF'></code><style id='3DB526F2EF'></style>
    • <acronym id='3DB526F2EF'></acronym>
      <center id='3DB526F2EF'><center id='3DB526F2EF'><tfoot id='3DB526F2EF'></tfoot></center><abbr id='3DB526F2EF'><dir id='3DB526F2EF'><tfoot id='3DB526F2EF'></tfoot><noframes id='3DB526F2EF'>

    • <optgroup id='3DB526F2EF'><strike id='3DB526F2EF'><sup id='3DB526F2EF'></sup></strike><code id='3DB526F2EF'></code></optgroup>
        1. <b id='3DB526F2EF'><label id='3DB526F2EF'><select id='3DB526F2EF'><dt id='3DB526F2EF'><span id='3DB526F2EF'></span></dt></select></label></b><u id='3DB526F2EF'></u>
          <i id='3DB526F2EF'><strike id='3DB526F2EF'><tt id='3DB526F2EF'><pre id='3DB526F2EF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          fashion

          author:hotspot    - browse:7
          Scorecard
          Ryan Pierse/Getty Images

          Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

          In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

          advertisement

          The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment